Collegium Pharmaceutical First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St · 05/10 13:52

Collegium Pharmaceutical (NASDAQ:COLL) First Quarter 2025 Results

Key Financial Results

  • Revenue: US$177.8m (up 23% from 1Q 2024).
  • Net income: US$2.42m (down 91% from 1Q 2024).
  • Profit margin: 1.4% (down from 19% in 1Q 2024).
  • EPS: US$0.076 (down from US$0.86 in 1Q 2024).
Our free stock report includes 4 warning signs investors should be aware of before investing in Collegium Pharmaceutical. Read for free now.
earnings-and-revenue-growth
NasdaqGS:COLL Earnings and Revenue Growth May 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Collegium Pharmaceutical Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) missed analyst estimates by 70%.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 4.5% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 4 warning signs for Collegium Pharmaceutical (of which 1 is a bit unpleasant!) you should know about.